https://m2.mtmt.hu/ hun 2026-09-22 01:36 JournalArticle 36246312 VALIDATED true Export Date: 23 October 2025; Cited By: 0; 0 false 2026-09-21T09:41:06.783+0000 2025-10-23T07:23:56.992+0000 2025-07-14T20:16:42.095+0000 true 10061232 Pethő Ákos /api/author/10061232 Author Pethő Ákos (Belgyógyászat, Nephrológia) true 10061232 2026-07-30T06:58:30.374+0000 2025-08-15T08:55:16.594+0000 true 10080205 Szalóky-Siki Ágnes /api/admin/10080205 Admin Szalóky-Siki Ágnes (SE_KK_Admin5_SZSA, admin) true true false true 24 24 /api/publicationtype/24 PublicationType Folyóiratcikk 1 true 24 JournalArticle true 1134514 Survey paper true 24 24 /api/publicationtype/24 PublicationType Folyóiratcikk 1 true 24 JournalArticle /api/subtype/1134514 Összefoglaló cikk SubType Összefoglaló cikk (Folyóiratcikk) 102 true 1134514 true 1 /api/category/1 Category Tudományos true 1 Pethő, Ákos Géza true true /api/journal/10028472 REVIEWED TOXINS 2072-6651 2072-6651 true false 10028472 false 10028472 true 2072-6651 2072-6651 Journal FOREIGN 17 7 345 345 20 2025 Background: Chronic kidney disease (CKD) is an established global health problem, with the increased prevalence of vascular inflammation, accelerated atherogenesis, and thrombotic risk all contributing to overall cardiovascular risk. The major CKD-specific risk factor is presumed to be the accumulation of uremic toxins in circulation and tissues, further accelerating the progression of CKD and its co-morbidities, including those of bone mineral disorders and cardiovascular diseases. Materials and Methods: In our narrative review, we focused on non-traditional cardiovascular risk factors, as they evolve with declined kidney function and are potentially further modulated by the choice of kidney replacement therapy. Results: Based on the data from the literature to date, the pre-eminent role of non-traditional risk factors emerges to mediate inflammation and increased cardiovascular mortality. In particular, patients receiving hemodialysis (HD) display dramatically increased CVD-mediated mortality. This intensified state of inflammation may be linked to the direct exposure of the bloodstream to a bio-incompatible environment in HD; for both complement-mediated and non-complement-mediated reactions, the possible contribution of neutrophil extracellular traps and complement activation-related pseudoallergy are reviewed in detail. Conclusions: Our narrative review emphasizes key elements of a bio-incompatible HD environment that may contribute to increased cardiovascular mortality in patients receiving HD. Summarizing these results may provide conceptual opportunities to develop new therapeutic targets. true true 2025 true true true false true false GOLD 2026-09-21 false http://www.mdpi.com/journal/toxins/ 10 0 10 10 0 10 10 9 10 10 10 10 10 10 0 0 10 10 10 10 0 20 20 Folyóiratcikk Journal Article 24 10 Könyvrészlet Chapter in Book 25 0 Könyv Book 23 0 Egyéb konferenciaközlemény Conference paper 31 0 Egyéb konferenciakötet Conference proceedings 32 0 Oltalmi formák Protection forms 26 0 Disszertáció Thesis 28 0 Egyéb Miscellaneous 29 0 Alkotás Achievement 22 0 Kutatási adat Research data 33 0 Folyóiratcikk Journal Article 24 0 0 0 Könyvrészlet Chapter in Book 25 0 0 0 Könyv Book 23 0 0 0 Egyéb konferenciaközlemény Conference paper 31 0 0 0 Egyéb konferenciakötet Conference proceedings 32 0 0 0 Oltalmi formák Protection forms 26 0 0 0 Disszertáció Thesis 28 0 0 0 Egyéb Miscellaneous 29 0 0 0 Alkotás Achievement 22 0 0 0 Kutatási adat Research data 33 0 0 0 2025 0 2 2 2 2 2026 0 8 8 8 8 Q2 false false false false 2025-08-04T08:11:55.703+0000 Belgyógyászati és Onkológiai Klinika (SE / AOK / K); Transzlációs Medicina Intézet (SE / AOK / I) 3 23 2 6 0 true Language 10002 /api/language/10002 Angol Angol English true 2 true PersonAuthorship 127260945 /api/authorship/127260945 Pethő, Ákos Géza ✉ [Pethő, Ákos (Belgyógyászat, Ne...), szerző] Belgyógyászati és Onkológiai Klinika (SE / AOK / K) 1 0.167 true false true Author 10061232 /api/author/10061232 Pethő Ákos (Belgyógyászat, Nephrológia) Pethő Ákos true 10061232 true Pethő Ákos Géza true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 127260946 /api/authorship/127260946 Fülöp, Tibor 2 0.16666667 false false false Fülöp Tibor true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 127260947 /api/authorship/127260947 Orosz, Petronella 3 0.16666667 false false false Orosz Petronella true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 127260948 /api/authorship/127260948 Szénási, Gábor [Szénási, Gábor (kórélettan), szerző] Transzlációs Medicina Intézet (SE / AOK / I) 4 0.167 false false false Author 10027489 /api/author/10027489 Szénási Gábor (kórélettan) Szénási Gábor true 10027489 true Szénási Gábor true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 127260949 /api/authorship/127260949 Tapolyai, Mihály 5 0.16666667 false false false Tapolyai Mihály true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 127260950 /api/authorship/127260950 Dézsi, László [Dézsi, László (Elméleti orvostud...), szerző] Transzlációs Medicina Intézet (SE / AOK / I) 6 0.167 false true false Author 10005165 /api/author/10005165 Dézsi László (Elméleti orvostudományok) Dézsi László true 10005165 true Dézsi László true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PublicationIdentifier 29595772 /api/publicationidentifier/29595772 DOI: 10.3390/toxins17070345 PlainSource 6 /api/publicationsource/6 DOI PublicationSourceType 10001 /api/publicationsourcetype/10001 DOI true true true DOI DOI https://doi.org/@@@ true true 6 true IDENTICAL 10.3390/toxins17070345 https://doi.org/10.3390/toxins17070345 false true PublicationIdentifier 29715651 /api/publicationidentifier/29715651 WoS: 001539618400001 PlainSource 1 /api/publicationsource/1 WoS PublicationSourceType 10003 /api/publicationsourcetype/10003 Indexelő adatbázis false true true WoS WoS https://www.webofscience.com/wos/woscc/full-record/@@@ true true 1 true IDENTICAL 001539618400001 https://www.webofscience.com/wos/woscc/full-record/001539618400001 true true PublicationIdentifier 29692582 /api/publicationidentifier/29692582 Scopus: 105011650549 PlainSource 3 /api/publicationsource/3 Scopus PublicationSourceType 10003 /api/publicationsourcetype/10003 Indexelő adatbázis false true true Scopus Scopus http://www.scopus.com/record/display.url?origin=inward&eid=2-s2.0-@@@ true true 3 true IDENTICAL 105011650549 http://www.scopus.com/record/display.url?origin=inward&eid=2-s2.0-105011650549 false true PublicationIdentifier 29715657 /api/publicationidentifier/29715657 PubMed: 40711156 PlainSource 17 /api/publicationsource/17 PubMed PublicationSourceType 10003 /api/publicationsourcetype/10003 Indexelő adatbázis false true true PubMed PubMed http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=@@@&dopt=Abstract true true 17 true IDENTICAL 40711156 http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=40711156&dopt=Abstract true true PublicationIdentifier 30050946 /api/publicationidentifier/30050946 Egyéb URL: https://www.scopus.com/inward/record.uri?eid=2-s2.0-105011650549&doi=10.3390%2Ftoxins17070345&partnerID=40&md5=18e60d0003de12dca31aa9f2d22f7640 PlainSource 40 /api/publicationsource/40 Egyéb URL PublicationSourceType 10006 /api/publicationsourcetype/10006 Link true true true Egyéb URL Other URL @@@ true true 40 true NONE IDENTICAL https://www.scopus.com/inward/record.uri?eid=2-s2.0-105011650549&doi=10.3390%2Ftoxins17070345&partnerID=40&md5=18e60d0003de12dca31aa9f2d22f7640 https://www.scopus.com/inward/record.uri?eid=2-s2.0-105011650549&doi=10.3390%2Ftoxins17070345&partnerID=40&md5=18e60d0003de12dca31aa9f2d22f7640 false true SjrRating 11821369 /api/sjrrating/11821369 sjr:Q2 (2025) Scopus - Health, Toxicology and Mutagenesis TOXINS 2072-6651 2072-6651 45 0.49 journal RatingType 10002 /api/ratingtype/10002 sjr sjr true true ClassificationExternal 2307 /api/classificationexternal/2307 Scopus - Health, Toxicology and Mutagenesis true 2307 true Q2 DIRECT true true Reference 66882067 /api/reference/66882067 1. Stevens 2024: KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease., Kidney Int., 105, p. S117, DOI: 10.1016/j.kint.2023.10.018 1 10.1016/j.kint.2023.10.018 false true Reference 66882068 /api/reference/66882068 2. Lv 2019: Prevalence and Disease Burden of Chronic Kidney Disease., Adv. Exp. Med. Biol., 1165, p. 3, DOI: 10.1007/978-981-13-8871-2_1 2 10.1007/978-981-13-8871-2_1 false true Reference 66882069 /api/reference/66882069 3. Sundstrom 2022: Prevalence, outcomes, and cost of chronic kidney disease in a contemporary population of 2.4 million patients from 11 countries: The CaReMe CKD study., Lancet Reg. Health Eur., 20, p. 100438, DOI: 10.1016/j.lanepe.2022.100438 3 10.1016/j.lanepe.2022.100438 false true Reference 66882070 /api/reference/66882070 4. Jager 2019: A single number for advocacy and communication-worldwide more than 850 million individuals have kidney diseases., Nephrol. Dial. Transplant., 34, p. 1803, DOI: 10.1093/ndt/gfz174 4 10.1093/ndt/gfz174 false true Reference 66882071 /api/reference/66882071 5. GBD Chronic Kidney Disease Collaboration (2020). Global, regional, and national burden of chronic kidney disease, 1990–2017: A systematic analysis for the Global Burden of Disease Study 2017. Lancet, 395, 709–733. 5 false true Reference 66882072 /api/reference/66882072 6. Foley 1998: Clinical epidemiology of cardiovascular disease in chronic renal disease., Am. J. Kidney Dis., 32, p. S112, DOI: 10.1053/ajkd.1998.v32.pm9820470 6 10.1053/ajkd.1998.v32.pm9820470 false true Reference 66882073 /api/reference/66882073 7. Neovius 2014: Mortality in chronic kidney disease and renal replacement therapy: A population-based cohort study., BMJ Open, 4, p. e004251, DOI: 10.1136/bmjopen-2013-004251 7 10.1136/bmjopen-2013-004251 false true Reference 66882074 /api/reference/66882074 8. Shahbazi, F., Doosti-Irani, A., Soltanian, A., and Poorolajal, J. (2024). Global forecasting of chronic kidney disease mortality rates and numbers with the generalized additive model. BMC Nephrol., 25., DOI: 10.1186/s12882-024-03720-w 8 10.1186/s12882-024-03720-w false true Reference 66882075 /api/reference/66882075 9. Broers 2015: The first year on haemodialysis: A critical transition., Clin. Kidney J., 8, p. 271, DOI: 10.1093/ckj/sfv021 9 10.1093/ckj/sfv021 false true Reference 66882076 /api/reference/66882076 10. Lukowsky 2012: Patterns and predictors of early mortality in incident hemodialysis patients: New insights., Am. J. Nephrol., 35, p. 548, DOI: 10.1159/000338673 10 10.1159/000338673 false true Reference 66882077 /api/reference/66882077 11. Gu, L., Xia, Z., Qing, B., Wang, W., Chen, H., Wang, J., Chen, Y., Gai, Z., Hu, R., and Yuan, Y. (2024). Systemic Inflammatory Response Index (SIRI) is associated with all-cause mortality and cardiovascular mortality in population with chronic kidney disease: Evidence from NHANES (2001–2018). Front. Immunol., 15., DOI: 10.3389/fimmu.2024.1338025 11 10.3389/fimmu.2024.1338025 false true Reference 66882078 /api/reference/66882078 12. Jungers 1996: New molecular aspects of chronic uraemia and dialysis-related immunocompetent cell activation., Nephrol. Dial. Transplant., 11, p. 121, DOI: 10.1093/ndt/11.supp2.121 12 10.1093/ndt/11.supp2.121 false true Reference 66882079 /api/reference/66882079 13. Crespo-Montero, R., Gomez-Lopez, V.E., Guerrero-Pavon, F., Carmona-Munoz, A., Romero-Saldana, M., Ranchal-Sanchez, A., and Aljama-Garcia, P. (2021). Influence of Tunneled Hemodialysis-Catheters on Inflammation and Mortality in Dialyzed Patients. Int. J. Environ. Res. Public Health, 18., DOI: 10.3390/ijerph18147605 13 10.3390/ijerph18147605 false true Reference 66882080 /api/reference/66882080 14. Tapolyai 2025: Prolonged use of dialysis catheters is associated with elevated chronic inflammatory markers: A single center case series., Ren. Fail., 47, p. 2478486, DOI: 10.1080/0886022X.2025.2478486 14 10.1080/0886022X.2025.2478486 false true Reference 66882081 /api/reference/66882081 15. Zsom 2010: Correlation of treatment time and ultrafiltration rate with serum albumin and C-reactive protein levels in patients with end-stage kidney disease receiving chronic maintenance hemodialysis: A cross-sectional study., Blood Purif., 30, p. 8, DOI: 10.1159/000314648 15 10.1159/000314648 false true Reference 66882082 /api/reference/66882082 16. Li 2021: Axl is related to inflammation in hemodialysis patients., Mol. Immunol., 133, p. 146, DOI: 10.1016/j.molimm.2021.02.024 16 10.1016/j.molimm.2021.02.024 false true Reference 66882083 /api/reference/66882083 17. Qureshi 2002: Inflammation, malnutrition, and cardiac disease as predictors of mortality in hemodialysis patients., J. Am. Soc. Nephrol., 13, p. S28, DOI: 10.1681/ASN.V13suppl_1s28 17 10.1681/ASN.V13suppl_1s28 false true Reference 66882084 /api/reference/66882084 18. Xiang, F., Cao, X., Chen, X., Zhang, Z., Ding, X., Zou, J., and Shen, B. (2021). Decreased Peripheral Naive T Cell Number and Its Role in Predicting Cardiovascular and Infection Events in Hemodialysis Patients. Front. Immunol., 12., DOI: 10.3389/fimmu.2021.644627 18 10.3389/fimmu.2021.644627 false true Reference 66882085 /api/reference/66882085 19. Badawy 2020: Interleukin 18 as a new inflammatory mediator in left ventricular hypertrophy in children with end-stage renal disease., Saudi J. Kidney Dis. Transplant. Off. Publ. Saudi Cent. Organ. Transplant. Saudi Arab., 31, p. 1206 19 false true Reference 66882086 /api/reference/66882086 20. Templier 2017: Transparency in literature reviews: An assessment of reporting practices across review types and genres in top IS journals., Eur. J. Inf. Syst., 27, p. 503, DOI: 10.1080/0960085X.2017.1398880 20 10.1080/0960085X.2017.1398880 false true Reference 66882087 /api/reference/66882087 21. Lau, F., and Kuziemsky, C. (2017). Methods for Literature Reviews. Handbook of eHealth Evaluation: An Evidence-Based Approach, University of Victoria. 21 false true Reference 66882088 /api/reference/66882088 22. Duranton 2012: Normal and pathologic concentrations of uremic toxins., J. Am. Soc. Nephrol., 23, p. 1258, DOI: 10.1681/ASN.2011121175 22 10.1681/ASN.2011121175 false true Reference 66882089 /api/reference/66882089 23. Vanholder 2003: Review on uremic toxins: Classification, concentration, and interindividual variability., Kidney Int., 63, p. 1934, DOI: 10.1046/j.1523-1755.2003.00924.x 23 10.1046/j.1523-1755.2003.00924.x false true Reference 66882090 /api/reference/66882090 24. Nissenson, A.R., Fine, R.N., Mehrotra, R., and Zaritsky, J. (2023). 47—Avoidance and Treatment of Cardiovascular Disease in Dialysis. Handbook of Dialysis Therapy, Elsevier. [6th ed.]. 24 false true Reference 66882091 /api/reference/66882091 25. Eloueyk 2019: Uremic Serum Induces Inflammation in Cultured Human Endothelial Cells and Triggers Vascular Repair Mechanisms., Inflammation, 42, p. 2003, DOI: 10.1007/s10753-019-01061-7 25 10.1007/s10753-019-01061-7 false true Reference 66882092 /api/reference/66882092 26. Sun 2018: Uremic toxins are conditional danger- or homeostasis-associated molecular patterns., Front. Biosci. (Landmark Ed.), 23, p. 348, DOI: 10.2741/4595 26 10.2741/4595 false true Reference 66882093 /api/reference/66882093 27. Nowak 2020: Vascular Dysfunction, Oxidative Stress, and Inflammation in Chronic Kidney Disease., Kidney360, 1, p. 501, DOI: 10.34067/KID.0000962019 27 10.34067/KID.0000962019 false true Reference 66882094 /api/reference/66882094 28. Weber 2011: Atherosclerosis: Current pathogenesis and therapeutic options., Nat. Med., 17, p. 1410, DOI: 10.1038/nm.2538 28 10.1038/nm.2538 false true Reference 66882095 /api/reference/66882095 29. Cai 2000: Endothelial dysfunction in cardiovascular diseases: The role of oxidant stress., Circ. Res., 87, p. 840, DOI: 10.1161/01.RES.87.10.840 29 10.1161/01.RES.87.10.840 false true Reference 66882096 /api/reference/66882096 30. Jerotic 2021: GSTM1 Modulates Expression of Endothelial Adhesion Molecules in Uremic Milieu., Oxid. Med. Cell. Longev., 2021, p. 6678924, DOI: 10.1155/2021/6678924 30 10.1155/2021/6678924 false true Reference 66882097 /api/reference/66882097 31. Ito 2010: Indoxyl sulfate induces leukocyte-endothelial interactions through up-regulation of E-selectin., J. Biol. Chem., 285, p. 38869, DOI: 10.1074/jbc.M110.166686 31 10.1074/jbc.M110.166686 false true Reference 66882098 /api/reference/66882098 32. Zsom 2019: The association of overhydration with chronic inflammation in chronic maintenance hemodiafiltration patients., Hemodial. Int., 23, p. 384, DOI: 10.1111/hdi.12742 32 10.1111/hdi.12742 false true Reference 66882099 /api/reference/66882099 33. Weiner 2007: The Framingham predictive instrument in chronic kidney disease., J. Am. Coll. Cardiol., 50, p. 217, DOI: 10.1016/j.jacc.2007.03.037 33 10.1016/j.jacc.2007.03.037 false true Reference 66882100 /api/reference/66882100 34. Roehm 2019: Blood pressure targets and kidney and cardiovascular disease: Same data but discordant guidelines., Curr. Opin. Nephrol. Hypertens., 28, p. 245, DOI: 10.1097/MNH.0000000000000492 34 10.1097/MNH.0000000000000492 false true Reference 66882101 /api/reference/66882101 35. Group 2008: Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes., N. Engl. J. Med., 358, p. 2560, DOI: 10.1056/NEJMoa0802987 35 10.1056/NEJMoa0802987 false true Reference 66882102 /api/reference/66882102 36. Zewinger 2017: Symmetric dimethylarginine, high-density lipoproteins and cardiovascular disease., Eur. Heart J., 38, p. 1597, DOI: 10.1093/eurheartj/ehx118 36 10.1093/eurheartj/ehx118 false true Reference 66882103 /api/reference/66882103 37. Ganesh 2003: Mortality differences by dialysis modality among incident ESRD patients with and without coronary artery disease., J. Am. Soc. Nephrol., 14, p. 415, DOI: 10.1097/01.ASN.0000043140.23422.4F 37 10.1097/01.ASN.0000043140.23422.4F false true Reference 66882104 /api/reference/66882104 38. Aeddula, A.S.M.F.H.N.R. (2024). Chronic Kidney Disease-Mineral Bone Disorder (CKD-MBD). StatPearls, StatPearls Publishing. 38 false true Reference 66882105 /api/reference/66882105 39. Shetty 2018: Calcific uremic arteriolopathy., Cleve Clin. J. Med., 85, p. 584, DOI: 10.3949/ccjm.85a.18009 39 10.3949/ccjm.85a.18009 false true Reference 66882106 /api/reference/66882106 40. Wang 2024: Individualizing the lifesaving journey for calciphylaxis: Addressing rapidly progressive attacks with multidimensional and AI research for regenerative medicine., Ren. Fail., 46, p. 2392846, DOI: 10.1080/0886022X.2024.2392846 40 10.1080/0886022X.2024.2392846 false true Reference 66882107 /api/reference/66882107 41. Amdur 2019: Use of Measures of Inflammation and Kidney Function for Prediction of Atherosclerotic Vascular Disease Events and Death in Patients With CKD: Findings from the CRIC Study., Am. J. Kidney Dis., 73, p. 344, DOI: 10.1053/j.ajkd.2018.09.012 41 10.1053/j.ajkd.2018.09.012 false true Reference 66882108 /api/reference/66882108 42. Marshall 2020: The benefit of early survival on PD versus HD-Why this is (still) very important., Perit. Dial. Int., 40, p. 405, DOI: 10.1177/0896860819895177 42 10.1177/0896860819895177 false true Reference 66882109 /api/reference/66882109 43. Fulop 2017: Peritoneal dialysis: The unique features by compartmental delivery of renal replacement therapy., Med. Hypotheses, 108, p. 128, DOI: 10.1016/j.mehy.2017.09.005 43 10.1016/j.mehy.2017.09.005 false true Reference 66882110 /api/reference/66882110 44. Velloso 2014: Peritoneal dialysis and inflammation., Clin. Chim. Acta, 430, p. 109, DOI: 10.1016/j.cca.2013.12.003 44 10.1016/j.cca.2013.12.003 false true Reference 66882111 /api/reference/66882111 45. Canaud 2020: Dialysis-Induced Cardiovascular and Multiorgan Morbidity., Kidney Int. Rep., 5, p. 1856, DOI: 10.1016/j.ekir.2020.08.031 45 10.1016/j.ekir.2020.08.031 false true Reference 66882112 /api/reference/66882112 46. Butani 2017: Hypersensitivity reactions in patients receiving hemodialysis., Ann. Allergy Asthma Immunol., 118, p. 680, DOI: 10.1016/j.anai.2017.04.006 46 10.1016/j.anai.2017.04.006 false true Reference 66882113 /api/reference/66882113 47. Saha 2017: Diagnosis, Treatment, and Prevention of Hemodialysis Emergencies., Clin. J. Am. Soc. Nephrol., 12, p. 357, DOI: 10.2215/CJN.05260516 47 10.2215/CJN.05260516 false true Reference 66882114 /api/reference/66882114 48. Kessler 1984: Anaphylactic reactions during hemodialysis: Responsibility of the dialysis membrane (cuprophan)., Nephrologie, 5, p. 119 48 false true Reference 66882115 /api/reference/66882115 49. Foley 1985: Acute Anaphylactoid Reactions in Hemodialysis., Am. J. Kidney Dis., 5, p. 132, DOI: 10.1016/S0272-6386(85)80010-X 49 10.1016/S0272-6386(85)80010-X false true Reference 66882116 /api/reference/66882116 50. Schaefer 1994: Anaphylactoid reactions during hemodialysis., Clin. Nephrol., 42, p. S44 50 false true Reference 66882117 /api/reference/66882117 51. Fulop 2019: Fatal anaphylactic shock in a patient undergoing hemodialysis via a polyurethane catheter., Clin. Nephrol., 92, p. 218, DOI: 10.5414/CN109888 51 10.5414/CN109888 false true Reference 66882118 /api/reference/66882118 52. Szebeni 2005: Complement activation-related pseudoallergy: A new class of drug-induced acute immune toxicity., Toxicology, 216, p. 106, DOI: 10.1016/j.tox.2005.07.023 52 10.1016/j.tox.2005.07.023 false true Reference 66882119 /api/reference/66882119 53. Mukaya 2015: Allergic reaction to polysulphone membrane dialyser masquerading as infection., BMJ Case Rep., 2015, p. bcr2014208591, DOI: 10.1136/bcr-2014-208591 53 10.1136/bcr-2014-208591 false true Reference 66882120 /api/reference/66882120 54. Yang 2005: Dialyzer reactions in a patient switching from peritoneal dialysis to hemodialysis., Hemodial. Int., 9, p. 120, DOI: 10.1111/j.1492-7535.2005.01123.x 54 10.1111/j.1492-7535.2005.01123.x false true Reference 66882121 /api/reference/66882121 55. Montagnac 1988: Hypersensitivity reactions during hemodialysis. Roles of high permeability, backfiltration and bacterial contamination of dialysis fluid., Nephrologie, 9, p. 29 55 false true Reference 66882122 /api/reference/66882122 56. Galan 1991: Anaphylactoid reactions in patients on hemodialysis with the AN69 membrane: The ACE inhibitors., Nefrologia, 11, p. 556 56 false true Reference 66882123 /api/reference/66882123 57. Davies 2001: Peritoneal glucose exposure and changes in membrane solute transport with time on peritoneal dialysis., J. Am. Soc. Nephrol., 12, p. 1046, DOI: 10.1681/ASN.V1251046 57 10.1681/ASN.V1251046 false true Reference 66882124 /api/reference/66882124 58. Krediet 2002: Peritoneal membrane failure in peritoneal dialysis patients., Blood Purif., 20, p. 489, DOI: 10.1159/000065202 58 10.1159/000065202 false true Reference 66882125 /api/reference/66882125 59. Witowski, J., Kamhieh-Milz, J., Kawka, E., Catar, R., and Jorres, A. (2018). IL-17 in Peritoneal Dialysis-Associated Inflammation and Angiogenesis: Conclusions and Perspectives. Front. Physiol., 9., DOI: 10.3389/fphys.2018.01694 59 10.3389/fphys.2018.01694 false true Reference 66882126 /api/reference/66882126 60. Craddock 1977: Hemodialysis leukopenia. Pulmonary vascular leukostasis resulting from complement activation by dialyzer cellophane membranes., J. Clin. Investig., 59, p. 879, DOI: 10.1172/JCI108710 60 10.1172/JCI108710 false true Reference 66882127 /api/reference/66882127 61. Craddock 1977: Complement and leukocyte-mediated pulmonary dysfunction in hemodialysis., N. Engl. J. Med., 296, p. 769, DOI: 10.1056/NEJM197704072961401 61 10.1056/NEJM197704072961401 false true Reference 66882128 /api/reference/66882128 62. Stepniewska 2020: The activation of complement system in different types of renal replacement therapy., J. Physiol. Pharmacol., 71, p. 275 62 false true Reference 66882129 /api/reference/66882129 63. Suzuki 1987: Acute changes in C3a and C5a in an anaphylactoid reaction in hemodialysis patients., Tohoku J. Exp. Med., 152, p. 35, DOI: 10.1620/tjem.152.35 63 10.1620/tjem.152.35 false true Reference 66882130 /api/reference/66882130 64. Hakim 1984: Biocompatibility of dialysis membranes: Effects of chronic complement activation., Kidney Int., 26, p. 194, DOI: 10.1038/ki.1984.155 64 10.1038/ki.1984.155 false true Reference 66882131 /api/reference/66882131 65. Vienken 1995: Considerations on developmental aspects of biocompatible dialysis membranes., Artif. Organs, 19, p. 398, DOI: 10.1111/j.1525-1594.1995.tb02349.x 65 10.1111/j.1525-1594.1995.tb02349.x false true Reference 66882132 /api/reference/66882132 66. Vanholder 1992: Biocompatibility issues in hemodialysis., Clin. Mater., 10, p. 87, DOI: 10.1016/0267-6605(92)90090-G 66 10.1016/0267-6605(92)90090-G false true Reference 66882133 /api/reference/66882133 67. Fiandor 2017: Mechanisms Involved in Hypersensitivity Reactions to Polysulfone Hemodialysis Membranes., Artif. Organs, 41, p. E285 67 false true Reference 66882134 /api/reference/66882134 68. Kiykim 2010: Pulmonary hypertension in hemodialysis patients without arteriovenous fistula: The effect of dialyzer composition., Ren. Fail., 32, p. 1148, DOI: 10.3109/0886022X.2010.516854 68 10.3109/0886022X.2010.516854 false true Reference 66882135 /api/reference/66882135 69. Gil 2007: Adverse reactions to polisulphone membrane dialyzers durind hemodialysis abstract., Nefrologia, 27, p. 638 69 false true Reference 66882136 /api/reference/66882136 70. Davis, B. (1968). Classification of allergic reactions responsible for drug hypersensitivity reactions. Clinical Aspects of Immunology, Davis. 70 false true Reference 66882137 /api/reference/66882137 71. Dezsi 2014: Features of complement activation-related pseudoallergy to liposomes with different surface charge and PEGylation: Comparison of the porcine and rat responses., J. Control. Release, 195, p. 2, DOI: 10.1016/j.jconrel.2014.08.009 71 10.1016/j.jconrel.2014.08.009 false true Reference 66882138 /api/reference/66882138 72. Kozma 2019: Pseudo-anaphylaxis to Polyethylene Glycol (PEG)-Coated Liposomes: Roles of Anti-PEG IgM and Complement Activation in a Porcine Model of Human Infusion Reactions., ACS Nano, 13, p. 9315, DOI: 10.1021/acsnano.9b03942 72 10.1021/acsnano.9b03942 false true Reference 66882139 /api/reference/66882139 73. Szebeni 1999: Hemodynamic changes induced by liposomes and liposome-encapsulated hemoglobin in pigs: A model for pseudoallergic cardiopulmonary reactions to liposomes. Role of complement and inhibition by soluble CR1 and anti-C5a antibody., Circulation, 99, p. 2302, DOI: 10.1161/01.CIR.99.17.2302 73 10.1161/01.CIR.99.17.2302 false true Reference 66882140 /api/reference/66882140 74. Szebeni 2006: Complement activation-related cardiac anaphylaxis in pigs: Role of C5a anaphylatoxin and adenosine in liposome-induced abnormalities in ECG and heart function., Am. J. Physiol. Heart Circ. Physiol., 290, p. H1050, DOI: 10.1152/ajpheart.00622.2005 74 10.1152/ajpheart.00622.2005 false true Reference 66882141 /api/reference/66882141 75. Szebeni 2012: A porcine model of complement-mediated infusion reactions to drug carrier nanosystems and other medicines., Adv. Drug Deliv. Rev., 64, p. 1706, DOI: 10.1016/j.addr.2012.07.005 75 10.1016/j.addr.2012.07.005 false true Reference 66882142 /api/reference/66882142 76. Szebeni 2012: Liposome-induced complement activation and related cardiopulmonary distress in pigs: Factors promoting reactogenicity of Doxil and AmBisome., Nanomedicine, 8, p. 176, DOI: 10.1016/j.nano.2011.06.003 76 10.1016/j.nano.2011.06.003 false true Reference 66882143 /api/reference/66882143 77. Szebeni 2012: Prevention of infusion reactions to PEGylated liposomal doxorubicin via tachyphylaxis induction by placebo vesicles: A porcine model., J. Control. Release, 160, p. 382, DOI: 10.1016/j.jconrel.2012.02.029 77 10.1016/j.jconrel.2012.02.029 false true Reference 66882144 /api/reference/66882144 78. Jackman 2016: Comparison of complement activation-related pseudoallergy in miniature and domestic pigs: Foundation of a validatable immune toxicity model., Nanomedicine, 12, p. 933, DOI: 10.1016/j.nano.2015.12.377 78 10.1016/j.nano.2015.12.377 false true Reference 66882145 /api/reference/66882145 79. Szebeni 2018: Mechanism of nanoparticle-induced hypersensitivity in pigs: Complement or not complement?., Drug Discov. Today, 23, p. 487, DOI: 10.1016/j.drudis.2018.01.025 79 10.1016/j.drudis.2018.01.025 false true Reference 66882146 /api/reference/66882146 80. Meszaros 2018: Involvement of complement activation in the pulmonary vasoactivity of polystyrene nanoparticles in pigs: Unique surface properties underlying alternative pathway activation and instant opsonization., Int. J. Nanomed., 13, p. 6345, DOI: 10.2147/IJN.S161369 80 10.2147/IJN.S161369 false true Reference 66882147 /api/reference/66882147 81. Dezsi 2022: A naturally hypersensitive porcine model may help understand the mechanism of COVID-19 mRNA vaccine-induced rare (pseudo) allergic reactions: Complement activation as a possible contributing factor., Geroscience, 44, p. 597, DOI: 10.1007/s11357-021-00495-y 81 10.1007/s11357-021-00495-y false true Reference 66882148 /api/reference/66882148 82. Bakos, T., Meszaros, T., Kozma, G.T., Berenyi, P., Facsko, R., Farkas, H., Dezsi, L., Heirman, C., de Koker, S., and Schiffelers, R. (2024). mRNA-LNP COVID-19 Vaccine Lipids Induce Complement Activation and Production of Proinflammatory Cytokines: Mechanisms, Effects of Complement Inhibitors, and Relevance to Adverse Reactions. Int. J. Mol. Sci., 25., DOI: 10.1101/2024.01.12.575122 82 10.1101/2024.01.12.575122 false true Reference 66882149 /api/reference/66882149 83. Milosevits 2021: Complement-mediated hypersensitivity reactions to an amphotericin B-containing lipid complex (Abelcet) in pediatric patients and anesthetized rats: Benefits of slow infusion., Nanomedicine, 34, p. 102366, DOI: 10.1016/j.nano.2021.102366 83 10.1016/j.nano.2021.102366 false true Reference 66882150 /api/reference/66882150 84. Nilsson 2007: The role of complement in biomaterial-induced inflammation., Mol. Immunol., 44, p. 82, DOI: 10.1016/j.molimm.2006.06.020 84 10.1016/j.molimm.2006.06.020 false true Reference 66882151 /api/reference/66882151 85. Ma 2017: Risk factors for mortality in patients undergoing hemodialysis: A systematic review and meta-analysis., Int. J. Cardiol., 238, p. 151, DOI: 10.1016/j.ijcard.2017.02.095 85 10.1016/j.ijcard.2017.02.095 false true Reference 66882152 /api/reference/66882152 86. Zhu, Y., Li, J., Lu, H., Shi, Z., and Wang, X. (2024). Effect of hemodiafiltration and hemodialysis on mortality of patients with end-stage kidney disease: A meta-analysis. BMC Nephrol., 25., DOI: 10.1186/s12882-024-03810-9 86 10.1186/s12882-024-03810-9 false true Reference 66882153 /api/reference/66882153 87. Brinkmann 2018: Neutrophil Extracellular Traps in the Second Decade., J. Innate Immun., 10, p. 414, DOI: 10.1159/000489829 87 10.1159/000489829 false true Reference 66882154 /api/reference/66882154 88. Yang 2023: Neutrophil extracellular trap is an important connection between hemodialysis and acute myocardial infarction., Ren. Fail., 45, p. 2216307, DOI: 10.1080/0886022X.2023.2216307 88 10.1080/0886022X.2023.2216307 false true Reference 66882155 /api/reference/66882155 89. Tan 2021: The vitals of NETs., J. Leukoc. Biol., 110, p. 797, DOI: 10.1002/JLB.3RU0620-375R 89 10.1002/JLB.3RU0620-375R false true Reference 66882156 /api/reference/66882156 90. Korabecna 2017: NETosis provides the link between activation of neutrophils on hemodialysis membrane and comorbidities in dialyzed patients., Inflamm. Res., 66, p. 369, DOI: 10.1007/s00011-016-1010-6 90 10.1007/s00011-016-1010-6 false true Reference 66882157 /api/reference/66882157 91. Lee, H.W., Nizet, V., An, J.N., Lee, H.S., Song, Y.R., Kim, S.G., and Kim, J.K. (2021). Uremic serum damages endothelium by provoking excessive neutrophil extracellular trap formation. Sci. Rep., 11., DOI: 10.1038/s41598-021-00863-w 91 10.1038/s41598-021-00863-w false true Reference 66882158 /api/reference/66882158 92. Bieber 2020: Neutrophil Activation and Neutrophil Extracellular Trap Formation in Dialysis Patients., Kidney Med., 2, p. 692, DOI: 10.1016/j.xkme.2020.06.014 92 10.1016/j.xkme.2020.06.014 false true Reference 66882159 /api/reference/66882159 93. Cheung 1986: Cardiopulmonary effects of cuprophane-activated plasma in the swine., Kidney Int., 29, p. 799, DOI: 10.1038/ki.1986.69 93 10.1038/ki.1986.69 false true Reference 66882160 /api/reference/66882160 94. Petho 2021: A porcine model of hemodialyzer reactions: Roles of complement activation and rinsing back of extracorporeal blood., Ren. Fail., 43, p. 1609, DOI: 10.1080/0886022X.2021.2007127 94 10.1080/0886022X.2021.2007127 false true Reference 66882161 /api/reference/66882161 95. Petho 2022: Pulmonary hypertension in a hemodialysis porcine model: Possible unforeseen causes?., Ren. Fail., 44, p. 693, DOI: 10.1080/0886022X.2022.2064305 95 10.1080/0886022X.2022.2064305 false true Reference 66882162 /api/reference/66882162 96. Tang 2018: Pulmonary Hypertension, Mortality, and Cardiovascular Disease in CKD and ESRD Patients: A Systematic Review and Meta-analysis., Am. J. Kidney Dis., 72, p. 75, DOI: 10.1053/j.ajkd.2017.11.018 96 10.1053/j.ajkd.2017.11.018 false true Reference 66882163 /api/reference/66882163 97. Edmonston 2020: Pulmonary Hypertension Subtypes and Mortality in CKD., Am. J. Kidney Dis., 75, p. 713, DOI: 10.1053/j.ajkd.2019.08.027 97 10.1053/j.ajkd.2019.08.027 false true Reference 66882164 /api/reference/66882164 98. Schoenberg 2020: Prevalence and Mortality of Pulmonary Hypertension in ESRD: A Systematic Review and Meta-analysis., Lung, 198, p. 535, DOI: 10.1007/s00408-020-00355-0 98 10.1007/s00408-020-00355-0 false true Reference 66882165 /api/reference/66882165 99. Utley 1990: Pathophysiology of cardiopulmonary bypass: Current issues., J. Card. Surg., 5, p. 177, DOI: 10.1111/j.1540-8191.1990.tb01036.x 99 10.1111/j.1540-8191.1990.tb01036.x false true Reference 66882166 /api/reference/66882166 100. Laffey 2002: The systemic inflammatory response to cardiac surgery: Implications for the anesthesiologist., Anesthesiology, 97, p. 215, DOI: 10.1097/00000542-200207000-00030 100 10.1097/00000542-200207000-00030 false true Reference 66882167 /api/reference/66882167 101. Davies 1997: Systemic inflammatory response syndrome., Br. J. Surg., 84, p. 920, DOI: 10.1002/bjs.1800840707 101 10.1002/bjs.1800840707 false true Reference 66882168 /api/reference/66882168 102. Paparella 2002: Cardiopulmonary bypass induced inflammation: Pathophysiology and treatment. An update., Eur. J. Cardiothorac. Surg., 21, p. 232, DOI: 10.1016/S1010-7940(01)01099-5 102 10.1016/S1010-7940(01)01099-5 false true Reference 66882169 /api/reference/66882169 103. Finn 1993: Interleukin-8 release and neutrophil degranulation after pediatric cardiopulmonary bypass., J. Thorac. Cardiovasc. Surg., 105, p. 234, DOI: 10.1016/S0022-5223(19)33806-1 103 10.1016/S0022-5223(19)33806-1 false true Reference 66882170 /api/reference/66882170 104. Edmunds 1995: Why cardiopulmonary bypass makes patients sick: Strategies to control the blood-synthetic surface interface., Adv. Card. Surg., 6, p. 131 104 false true Reference 66882171 /api/reference/66882171 105. Li 2012: Early and marked up-regulation of TNF-alpha in acute respiratory distress syndrome after cardiopulmonary bypass., Front. Med., 6, p. 296, DOI: 10.1007/s11684-012-0219-1 105 10.1007/s11684-012-0219-1 false true Reference 66882172 /api/reference/66882172 106. Cave 1993: Thromboxane A2 mediates pulmonary hypertension after cardiopulmonary bypass in the rabbit., J. Thorac. Cardiovasc. Surg., 106, p. 959, DOI: 10.1016/S0022-5223(19)33966-2 106 10.1016/S0022-5223(19)33966-2 false true Reference 66882173 /api/reference/66882173 107. Kovesdy 2022: Epidemiology of chronic kidney disease: An update 2022., Kidney Int. Suppl., 12, p. 7, DOI: 10.1016/j.kisu.2021.11.003 107 10.1016/j.kisu.2021.11.003 false true Reference 66882174 /api/reference/66882174 108. Petrie 2018: Diabetes, hypertension, and cardiovascular disease: Clinical insights and vascular mechanisms., Can. J. Cardiol., 34, p. 575, DOI: 10.1016/j.cjca.2017.12.005 108 10.1016/j.cjca.2017.12.005 false true Reference 66882175 /api/reference/66882175 109. Li 2023: Fragmented QRS complex on a 12-lead electrocardiogram predicts cardiovascular and all-cause mortality in dialysis patients., Semin. Dial., 36, p. 43, DOI: 10.1111/sdi.13055 109 10.1111/sdi.13055 false true Reference 66882176 /api/reference/66882176 110. Franklin 2013: Hypertension and Cardiovascular Disease: Contributions of the Framingham Heart Study., Glob. Heart, 8, p. 49, DOI: 10.1016/j.gheart.2012.12.004 110 10.1016/j.gheart.2012.12.004 false true Reference 66882177 /api/reference/66882177 111. Wang 2020: Association of age of onset of hypertension with cardiovascular diseases and mortality., J. Am. Coll. Cardiol., 75, p. 2921, DOI: 10.1016/j.jacc.2020.04.038 111 10.1016/j.jacc.2020.04.038 false true Reference 66882178 /api/reference/66882178 112. Kannel 1979: Diabetes and cardiovascular disease: The Framingham study., JAMA, 241, p. 2035, DOI: 10.1001/jama.1979.03290450033020 112 10.1001/jama.1979.03290450033020 false true Reference 66882179 /api/reference/66882179 113. Resnick 2002: Diabetes and cardiovascular disease., Annu. Rev. Med., 53, p. 245, DOI: 10.1146/annurev.med.53.082901.103904 113 10.1146/annurev.med.53.082901.103904 false true Reference 66882180 /api/reference/66882180 114. Matheus 2013: Impact of diabetes on cardiovascular disease: An update., Int. J. Hypertens., 2013, p. 653789, DOI: 10.1155/2013/653789 114 10.1155/2013/653789 false true Reference 66882181 /api/reference/66882181 115. Gonna 2019: The importance of dyslipidaemia in the pathogenesis of cardiovascular disease in people with diabetes., Diabetes Obes. Metab., 21, p. 6, DOI: 10.1111/dom.13691 115 10.1111/dom.13691 false true Reference 66882182 /api/reference/66882182 116. Lorenzatti 2020: New perspectives on atherogenic dyslipidaemia and cardiovascular disease., Eur. Cardiol. Rev., 15, p. e04, DOI: 10.15420/ecr.2019.06 116 10.15420/ecr.2019.06 false true Reference 66882183 /api/reference/66882183 117. Pascual 2017: Chronic kidney disease and dyslipidaemia., Clínica Investig. Arterioscler. (Engl. Ed.), 29, p. 22 117 false true Reference 66882184 /api/reference/66882184 118. McClelland 2018: Coronary heart disease risk associated with the dyslipidaemia of chronic kidney disease., Heart, 104, p. 1455, DOI: 10.1136/heartjnl-2017-312794 118 10.1136/heartjnl-2017-312794 false true Reference 66882185 /api/reference/66882185 119. Grzegorzewska, A.E., Adamska, P., Iwanczyk-Skalska, E., Ostromecka, K., Niepolski, L., Marcinkowski, W., Mostowska, A., Warchol, W., Zaba, C., and Jagodzinski, P.P. (2021). Paraoxonase 1 concerning dyslipidaemia, cardiovascular diseases, and mortality in haemodialysis patients. Sci. Rep., 11., DOI: 10.1038/s41598-021-86231-0 119 10.1038/s41598-021-86231-0 false true Reference 66882186 /api/reference/66882186 120. Martin 2007: Metabolic bone disease in chronic kidney disease., J. Am. Soc. Nephrol., 18, p. 875, DOI: 10.1681/ASN.2006070771 120 10.1681/ASN.2006070771 false true Reference 66882187 /api/reference/66882187 121. Foley 2000: Effects of anaemia on cardiovascular status., Nephrol. Dial. Transplant., 15, p. 19, DOI: 10.1093/oxfordjournals.ndt.a027971 121 10.1093/oxfordjournals.ndt.a027971 false true Reference 66882188 /api/reference/66882188 122. Sarnak 2002: Anemia as a risk factor for cardiovascular disease in The Atherosclerosis Risk in Communities (ARIC) study., J. Am. Coll. Cardiol., 40, p. 27, DOI: 10.1016/S0735-1097(02)01938-1 122 10.1016/S0735-1097(02)01938-1 false true Reference 66882189 /api/reference/66882189 123. Lanser, L., Fuchs, D., Scharnagl, H., Grammer, T., Kleber, M.E., März, W., Weiss, G., and Kurz, K. (2021). Anemia of chronic disease in patients with cardiovascular disease. Front. Cardiovasc. Med., 8., DOI: 10.3389/fcvm.2021.666638 123 10.3389/fcvm.2021.666638 false true Reference 66882190 /api/reference/66882190 124. Mikhail, A., Brown, C., Williams, J.A., Mathrani, V., Shrivastava, R., Evans, J., Isaac, H., and Bhandari, S. (2017). Renal association clinical practice guideline on Anaemia of Chronic Kidney Disease. BMC Nephrol., 18., DOI: 10.1186/s12882-017-0688-1 124 10.1186/s12882-017-0688-1 false true Reference 66882191 /api/reference/66882191 125. Stauffer, M.E., and Fan, T. (2014). Prevalence of anemia in chronic kidney disease in the United States. PLoS ONE, 9., DOI: 10.1371/journal.pone.0084943 125 10.1371/journal.pone.0084943 false true Reference 66882192 /api/reference/66882192 126. Murdeshwar, H.N., and Anjum, F. (2025). Hemodialysis, StatPearls. 126 false true Reference 66882193 /api/reference/66882193 127. Bello 2022: Epidemiology of haemodialysis outcomes., Nat. Rev. Nephrol., 18, p. 378, DOI: 10.1038/s41581-022-00542-7 127 10.1038/s41581-022-00542-7 false true Reference 66882194 /api/reference/66882194 128. Jung, H.Y., Jeon, Y., Kim, Y.S., Kang, S.W., Yang, C.W., Kim, N.H., Noh, H.W., Jeon, S.J., Lim, J.H., and Choi, J.Y. (2022). Sex disparities in mortality among patients with kidney failure receiving dialysis. Sci. Rep., 12., DOI: 10.1038/s41598-022-16163-w 128 10.1038/s41598-022-16163-w false true Reference 66882195 /api/reference/66882195 129. Tan 2020: Effects of Carvedilol on Cardiovascular Events and Mortality in Hemodialysis Patients, A Systematic Review and Meta-Analysis., Iran. J. Kidney Dis., 14, p. 256 129 false true Reference 66882196 /api/reference/66882196 130. Maki, K.C., Wilcox, M.L., Dicklin, M.R., Kakkar, R., and Davidson, M.H. (2022). Left ventricular mass regression, all-cause and cardiovascular mortality in chronic kidney disease: A meta-analysis. BMC Nephrol., 23., DOI: 10.1186/s12882-022-02666-1 130 10.1186/s12882-022-02666-1 false true Reference 66882197 /api/reference/66882197 131. Zimmermann 1999: Inflammation enhances cardiovascular risk and mortality in hemodialysis patients., Kidney Int., 55, p. 648, DOI: 10.1046/j.1523-1755.1999.00273.x 131 10.1046/j.1523-1755.1999.00273.x false true Reference 66882198 /api/reference/66882198 132. Ebert, T., Pawelzik, S.C., Witasp, A., Arefin, S., Hobson, S., Kublickiene, K., Shiels, P.G., Back, M., and Stenvinkel, P. (2020). Inflammation and Premature Ageing in Chronic Kidney Disease. Toxins, 12., DOI: 10.3390/toxins12040227 132 10.3390/toxins12040227 false true Reference 66882199 /api/reference/66882199 133. Ulrich, C., Wildgrube, S., Fiedler, R., Seibert, E., Kneser, L., Fick, S., Schafer, C., Markau, S., Trojanowicz, B., and Girndt, M. (2020). NLRP3 Inflammasome Activation in Hemodialysis and Hypertensive Patients with Intact Kidney Function. Toxins, 12., DOI: 10.3390/toxins12110675 133 10.3390/toxins12110675 false true Reference 66882200 /api/reference/66882200 134. Li 2017: High Neutrophil-to-Lymphocyte Ratio Predicts Cardiovascular Mortality in Chronic Hemodialysis Patients., Mediat. Inflamm., 2017, p. 9327136, DOI: 10.1155/2017/9327136 134 10.1155/2017/9327136 false true Reference 66882201 /api/reference/66882201 135. Kumbar 2019: Current Concepts in Hemodialysis Vascular Access Infections., Adv. Chronic Kidney Dis., 26, p. 16, DOI: 10.1053/j.ackd.2018.10.005 135 10.1053/j.ackd.2018.10.005 false true Reference 66882202 /api/reference/66882202 136. Almeida 2022: Interventions for treating catheter-related bloodstream infections in people receiving maintenance haemodialysis., Cochrane Database Syst. Rev., 4, p. CD013554 136 false true Reference 66882203 /api/reference/66882203 137. Balbino 2018: Polymorphism related to cardiovascular risk in hemodialysis subjects: A systematic review., J. Bras. Nefrol., 40, p. 179, DOI: 10.1590/2175-8239-jbn-3857 137 10.1590/2175-8239-jbn-3857 false true Reference 66882204 /api/reference/66882204 138. Mineshima 2017: Optimal Design of Dialyzers., Contrib. Nephrol., 189, p. 204, DOI: 10.1159/000450802 138 10.1159/000450802 false true Reference 66882205 /api/reference/66882205 139. Lemke 1985: Mechanisms of hypersensitivity reactions during hemodialysis., Trans.-Am. Soc. Artif. Intern. Organs, 31, p. 149 139 false true Reference 66882206 /api/reference/66882206 140. Pinheiro 2011: Anaphylactic reaction induced by a polysulfone/polyvinylpyrrolidone membrane in the 10th session of hemodialysis with the same dialyzer., Hemodial. Int., 15, p. 399, DOI: 10.1111/j.1542-4758.2011.00553.x 140 10.1111/j.1542-4758.2011.00553.x false true Reference 66882207 /api/reference/66882207 141. Boer 2017: Acute reactions to polysulfone/polyethersulfone dialysers: Literature review and management., Neth. J. Med., 75, p. 4 141 false true Reference 66882208 /api/reference/66882208 142. Dahe 2011: The biocompatibility and separation performance of antioxidative polysulfone/vitamin E TPGS composite hollow fiber membranes., Biomaterials, 32, p. 352, DOI: 10.1016/j.biomaterials.2010.09.005 142 10.1016/j.biomaterials.2010.09.005 false true Reference 66882209 /api/reference/66882209 143. Kohlová, M., Rocha, S., Gomes Amorim, C., de Nova Araújo, A., Santos-Silva, A., Solich, P., and Branco da Silva Montenegro, M.C. (2020). Doping Polysulfone Membrane with Alpha-Tocopherol and Alpha-Lipoic Acid for Suppressing Oxidative Stress Induced by Hemodialysis Treatment. Macromol. Biosci., 20., DOI: 10.1002/mabi.202000046 143 10.1002/mabi.202000046 false true Reference 66882210 /api/reference/66882210 144. Yamamoto 2007: Antioxidation property of vitamin E-coated polysulfone dialysis membrane and recovery of oxidized vitamin E by vitamin C treatment., J. Membr. Sci., 302, p. 115, DOI: 10.1016/j.memsci.2007.06.038 144 10.1016/j.memsci.2007.06.038 false true Reference 66882211 /api/reference/66882211 145. Panichi 2011: A vitamin E-coated polysulfone membrane reduces serum levels of inflammatory markers and resistance to erythropoietin-stimulating agents in hemodialysis patients: Results of a randomized cross-over multicenter trial., Blood Purif., 32, p. 7, DOI: 10.1159/000321369 145 10.1159/000321369 false true Reference 66882212 /api/reference/66882212 146. Amorim, C., Montenegro, M., Araujo, A., Kohlová, M., Solich, P., and Zelena, L. (2018, January 26–27). Preparation of Polysulfone Membrane with α-Tocopherol and α Lipoic acid to Reduce Oxidative Stress. Proceedings of the 9th Meeting of Division of Analytical Chemistry, Porto, Portugal. 146 false true Reference 66882213 /api/reference/66882213 147. Li 2023: Alleviation of Oxidative Stress during Hemodialysis Sessions by Hemodialysis Membrane Innovation: A Multidisciplinary Perspective., Blood Purif., 52, p. 905, DOI: 10.1159/000533656 147 10.1159/000533656 false true Reference 66882214 /api/reference/66882214 148. 2016: The complement system in hemodialysis patients: Getting to the heart of the matter., Nephron, 132, p. 1, DOI: 10.1159/000443340 148 10.1159/000443340 false true Reference 66882215 /api/reference/66882215 149. Skinner 2021: Hemodialysis-related complement and contact pathway activation and cardiovascular risk: A narrative review., Kidney Med., 3, p. 607, DOI: 10.1016/j.xkme.2021.04.006 149 10.1016/j.xkme.2021.04.006 false true Reference 66882216 /api/reference/66882216 150. Cozzolino 2018: Cardiovascular disease in dialysis patients., Nephrol. Dial. Transplant., 33, p. 328, DOI: 10.1093/ndt/gfy174 150 10.1093/ndt/gfy174 false true Reference 66882217 /api/reference/66882217 151. Vonesh 2004: The differential impact of risk factors on mortality in hemodialysis and peritoneal dialysis., Kidney Int., 66, p. 2389, DOI: 10.1111/j.1523-1755.2004.66028.x 151 10.1111/j.1523-1755.2004.66028.x false true Reference 66882218 /api/reference/66882218 152. Chander, S., Luhana, S., Sadarat, F., Parkash, O., Rahaman, Z., Wang, H.Y., Kiran, F., Lohana, A.C., Sapna, F., and Kumari, R. (2024). Mortality and mode of dialysis: Meta-analysis and systematic review. BMC Nephrol., 25., DOI: 10.1186/s12882-023-03435-4 152 10.1186/s12882-023-03435-4 false true Reference 66882219 /api/reference/66882219 153. Ethier 2024: Peritoneal dialysis versus haemodialysis for people commencing dialysis., Cochrane Database Syst. Rev., 6, p. CD013800 153 false true Reference 66882220 /api/reference/66882220 154. Baroni 2012: Inflammation and the peritoneal membrane: Causes and impact on structure and function during peritoneal dialysis., Mediat. Inflamm., 2012, p. 912595, DOI: 10.1155/2012/912595 154 10.1155/2012/912595 false true Reference 66882221 /api/reference/66882221 155. Flessner 2007: Peritoneal changes after exposure to sterile solutions by catheter., J. Am. Soc. Nephrol., 18, p. 2294, DOI: 10.1681/ASN.2006121417 155 10.1681/ASN.2006121417 false true Reference 66882222 /api/reference/66882222 156. Razeghi 2008: Chronic inflammation increases risk in hemodialysis patients., Saudi J. Kidney Dis. Transplant., 19, p. 785 156 false true Reference 66882223 /api/reference/66882223 157. Lonnemann 2000: Chronic inflammation in hemodialysis: The role of contaminated dialysate., Blood Purif., 18, p. 214, DOI: 10.1159/000014420 157 10.1159/000014420 false true Reference 66882224 /api/reference/66882224 158. Cobo 2018: Chronic inflammation in end-stage renal disease and dialysis., Nephrol. Dial. Transplant., 33, p. 335, DOI: 10.1093/ndt/gfy175 158 10.1093/ndt/gfy175 false true Reference 66882225 /api/reference/66882225 159. Spittle 2001: Oxidative stress and inflammation in hemodialysis patients., Am. J. Kidney Dis., 38, p. 1408, DOI: 10.1053/ajkd.2001.29280 159 10.1053/ajkd.2001.29280 false true Reference 66882226 /api/reference/66882226 160. Wang, Y., and Gao, L. (2022). Inflammation and cardiovascular disease associated with hemodialysis for end-stage renal disease. Front. Pharmacol., 13., DOI: 10.3389/fphar.2022.800950 160 10.3389/fphar.2022.800950 false true Reference 66882227 /api/reference/66882227 161. Dheda 2022: Effect of a hemodialysis session on markers of inflammation and endotoxin., Int. J. Inflamm., 2022, p. 8632245 161 false true Reference 66882228 /api/reference/66882228 162. Ebert 2021: Inflammation and oxidative stress in chronic kidney disease and dialysis patients., Antioxid. Redox Signal., 35, p. 1426, DOI: 10.1089/ars.2020.8184 162 10.1089/ars.2020.8184 false true Reference 66882229 /api/reference/66882229 163. Ji 2023: Advances in enhancing hemocompatibility of hemodialysis hollow-fiber membranes., Adv. Fiber Mater., 5, p. 1198, DOI: 10.1007/s42765-023-00277-5 163 10.1007/s42765-023-00277-5 false true Reference 66882230 /api/reference/66882230 164. Motofelea, A.C., Mihaescu, A., Olariu, N., Marc, L., Chisavu, L., Pop, G.N., Crintea, A., Jura, A.M.C., Ivan, V.M., and Apostol, A. (2025). Machine Learning Models for Predicting Mortality in Hemodialysis Patients: A Systematic Review. Appl. Sci., 15., DOI: 10.3390/app15105776 164 10.3390/app15105776 false true /api/publication/36246312 Pethő Ákos Géza et al. Increased Cardiovascular Mortality in Hemodialysis: The Role of Chronic Inflammation, Complement Activation, and Non-Biocompatibility. (2025) TOXINS 2072-6651 2072-6651 17 7<div class="JournalArticle Publication long-list"> <div class="authors"> <img title="Forrásközlemény" style="float: left" src="/frontend/resources/grid/publication-core-icon.png"> <img title="Idézőközlemény" style="float: left" src="/frontend/resources/grid/publication-citation-icon.png"> <div class="autype autype0"> <span class="author-name" mtid="10061232"><a href="/gui2/?type=authors&mode=browse&sel=10061232" target="_blank">Pethő Ákos Géza ✉ (<span class="authorship-author-name">Pethő Ákos</span> <span class="authorAux-mtmt"> Belgyógyászat, Nephrológia</span>) </a> </span> <span class="author-affil"><span title="Semmelweis Egyetem">SE</span>/<span title="Általános Orvostudományi Kar">AOK</span>/<span title="Klinikum">K</span>/Belgyógyászati és Onkológiai Klinika</span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" >Fülöp Tibor </span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" >Orosz Petronella </span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" mtid="10027489"><a href="/gui2/?type=authors&mode=browse&sel=10027489" target="_blank">Szénási Gábor (<span class="authorship-author-name">Szénási Gábor</span> <span class="authorAux-mtmt"> kórélettan</span>) </a> </span> <span class="author-affil"><span title="Semmelweis Egyetem">SE</span>/<span title="Általános Orvostudományi Kar">AOK</span>/<span title="Intézet">I</span>/Transzlációs Medicina Intézet</span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" >Tapolyai Mihály </span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" mtid="10005165"><a href="/gui2/?type=authors&mode=browse&sel=10005165" target="_blank">Dézsi László (<span class="authorship-author-name">Dézsi László</span> <span class="authorAux-mtmt"> Elméleti orvostudományok</span>) </a> </span> <span class="author-affil"><span title="Semmelweis Egyetem">SE</span>/<span title="Általános Orvostudományi Kar">AOK</span>/<span title="Intézet">I</span>/Transzlációs Medicina Intézet</span> </div> </div> <div class="title"><a href="/gui2/?mode=browse&params=publication;36246312" target="_blank">Increased Cardiovascular Mortality in Hemodialysis: The Role of Chronic Inflammation, Complement Activation, and Non-Biocompatibility</a></div> <div> <span class="journal-title">TOXINS</span> <span class="journal-issn">(<a target="_blank" href="https://portal.issn.org/resource/ISSN/2072-6651">2072-6651</a> <a target="_blank" href="https://portal.issn.org/resource/ISSN/2072-6651">2072-6651</a>)</span>: <span class="journal-volume">17</span> <span class="journal-issue">7</span> <span class="page"> Paper 345. 20 p. </span> <span class="year">(2025)</span> </div> <div class="pub-footer"> <span class="language" xmlns="http://www.w3.org/1999/html">Nyelv: Angol | </span> <span class="identifiers"> <span class="id identifier oa_none" title="none"> <a style="color:blue" title="10.3390/toxins17070345" target="_blank" href="https://doi.org/10.3390/toxins17070345"> DOI </a> </span> <span class="id identifier oa_none" title="none"> <a style="color:blue" title="001539618400001" target="_blank" href="https://www.webofscience.com/wos/woscc/full-record/001539618400001"> WoS </a> </span> <span class="id identifier oa_none" title="none"> <a style="color:blue" title="105011650549" target="_blank" href="http://www.scopus.com/record/display.url?origin=inward&eid=2-s2.0-105011650549"> Scopus </a> </span> <span class="id identifier oa_none" title="none"> <a style="color:blue" title="40711156" target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=40711156&dopt=Abstract"> PubMed </a> </span> <span class="id identifier oa_NONE" title=" Nincs "> <a style="color:blue" title="https://www.scopus.com/inward/record.uri?eid=2-s2.0-105011650549&doi=10.3390%2Ftoxins17070345&partnerID=40&md5=18e60d0003de12dca31aa9f2d22f7640" target="_blank" href="https://www.scopus.com/inward/record.uri?eid=2-s2.0-105011650549&doi=10.3390%2Ftoxins17070345&partnerID=40&md5=18e60d0003de12dca31aa9f2d22f7640"> Egyéb URL </a> </span> </span> <OnlyViewableByAuthor><div class="ratings"> <div class="journal-subject">Folyóirat szakterülete: Scopus - Health, Toxicology and Mutagenesis&nbsp;&nbsp;&nbsp;SJR indikátor:&nbsp;Q2</div> <div class="journal-subject">Folyóirat szakterülete: Scopus - Toxicology&nbsp;&nbsp;&nbsp;SJR indikátor:&nbsp;Q2</div> </div></OnlyViewableByAuthor> <div class="publication-citation" style="margin-left: 0.5cm;"> <span title="Nyilvános idézőközlemények összesen, említések nélkül" class="citingPub-count">Nyilvános idéző összesen: 10</span> | Független: 10 | Függő: 0 | Nem jelölt: 0 | WoS jelölt: 9 | Scopus jelölt:&nbsp;10 | WoS/Scopus jelölt:&nbsp;10 | DOI jelölt:&nbsp;10 </div> <div class="publication-citation"> <a target="_blank" href="/api/publication?cond=citations.related;eq;36246312&sort=publishedYear,desc&sort=title"> Idézett közlemények száma: 20 </a> </div> <div class="mtid"><span class="long-pub-mtid">Közlemény: 36246312</span> | <span class="status-data status-VALIDATED"> Egyeztetett </span> Forrás Idéző | <span class="type-subtype">Folyóiratcikk ( Összefoglaló cikk ) </span> | <span class="pub-category">Tudományos</span> | <span class="publication-sourceOfData">Scopus</span> </div> <div class="lastModified">Utolsó módosítás: 2025.10.23. 09:23 Molnár-Taga Márta (SE 4-es admin) </div> <pre class="comment" style="margin-top: 0; margin-bottom: 0;"><u>Megjegyzés</u>: Export Date: 23 October 2025; Cited By: 0;</pre> </div></div>